× Key messages Background Findings Perspectives Expert commentary

Perspectives

How does this impact clinical practice?

  • New drugs aim to increase the anti-tumour immune response.
  • There is a need to be highly selective about which patients receive some of these emerging options once they become available.
  • For example, about half of patients drop out between the TIL harvest and infusion required for lifileucel therapy.